Table 1.
Hemodynamics of focal hepatic lesions on contrast-enhanced C-cube gray scale ultrasonography
| Types of lesion | No. of lesions |
Injection-enhancement delay
time (mean ± SD) (s) |
Enhancement duration (mean ± SD) (s) |
|||
| Liver | Lesion | P Value | Lesion | P Value | ||
| Primary liver cancer | 29 | 33 ± 10 | 23 ± 6 | < 0.05 | 69 ± 33b | — |
| Metastasis | 4 | 26 ± 7 | 26 ± 11 | < 0.05 | 59 ± 22c | — |
| Hemangioma | 8 | 36 ± 8 | 48 ± 12a | — | 221 ± 47 | < 0.05 |
| Focal nodular hyperplasia | 12 | 29 ± 9 | 20 ± 6 | < 0.05 | 196 ± 96 | < 0.05 |
| Angiomyolipoma | 3 | 37 ± 12 | 26 ± 6 | < 0.05 | 177 ± 90 | < 0.05 |
The injection-enhancement delay time after administration of Levovist in hemangioma was significantly longer than that in other types of lesions (P < 0.05).
The enhancement duration in primary liver cancer was significantly shorter than that in benign lesions (P < 0.05).
The enhancement duration in metastasis was significantly shorter than that in benign lesions (P < 0.05).